---
title: "Yili Chuanning Biotechnology Co., Ltd. (301301.SZ)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/301301.SZ.md"
symbol: "301301.SZ"
name: "Yili Chuanning Biotechnology Co., Ltd."
industry: "Biotechnology"
---

# Yili Chuanning Biotechnology Co., Ltd. (301301.SZ)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | CN Market |
| Website | [www.klcnsw.com](https://www.klcnsw.com) |

## Company Profile

Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. The company offers antibiotic intermediates comprising erythromycin thiofluor...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:10.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 24 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -16.85% |  |
| Net Profit YoY | -32.01% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.07 |  |
| Dividend Ratio | 2.47% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 24.35B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 4.74B |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 12.08% | B |
| Profit Margin | 19.75% | A |
| Gross Margin | 28.64% | C |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -16.85% | E |
| Net Profit YoY | -32.01% | D |
| Total Assets YoY | -2.09% | D |
| Net Assets YoY | 4.77% | C |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 506.31% | C |
| OCF YoY | -16.85% | E |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.45 | C |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 23.03% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Yili Chuanning Biotechnology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "12.08%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "19.75%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "28.64%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-16.85%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-32.01%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.09%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "4.77%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "506.31%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-16.85%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.45",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "23.03%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BeOne Medicines (SH.688235) | C | A | B | C | A | B |
| 02 | Gan & Lee (SH.603087) | B | B | D | A | B | B |
| 03 | Sunshine Guojian Pharmaceutical (SH.688336) | A | B | D | B | C | B |
| 04 | Biocytogen (SH.688796) | A | A | C | D | B | B |
| 05 | BTBP (SH.600161) | B | B | C | A | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 26.02 | 7/83 | 25.31 | 22.08 | 20.43 |
| PB | 3.07 | 41/83 | 3.50 | 3.28 | 3.09 |
| PS (TTM) | 5.14 | 16/83 | 5.23 | 5.03 | 4.84 |
| Dividend Yield | 2.47% | 7/83 | 2.47% | 2.27% | 1.91% |

## Institutional View

### Analyst Rating Distribution

> As of 2026-01-21T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 10.92 |
| Highest Target | 13.00 |
| Lowest Target | 13.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/301301.SZ/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/301301.SZ/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/301301.SZ/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.